You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

CMEC Meeting 37, 29-30 August 2002

Complementary Medicines Evaluation Committee

29 August 2002

Extracted ratified minutes

How to access a pdf document

CMEC Meeting 37 extracted ratified minutes (pdf,68kb)

Public recommendation summary

This summary has been posted immediately after the CMEC meeting to give quick advice of the recommendations made by CMEC to the TGA. This summary does not represent the decisions of TGA. Reasons underlying these recommendations will be available after Members ratify the Minutes at the next CMEC meeting.

Item 2 Minutes of CMEC's 36th meeting

Recommendation 37.1

CMEC confirms that the draft Minutes of its previous meeting (CMEC 36, 26 July 2002), as amended, are a true and accurate record of that previous meeting.

Item 5 Action arising from previous meetings

Item 5.2 Folic acid dissolution requirement

Recommendation 37.3

CMEC recommends to the TGA that:

  • All tablets containing 400 micrograms or more of folic acid should comply with the proposed dissolution requirements by 25 November 2002 and publicity be directed to health professionals and information be posted on the TGA website advising that products containing 400 micrograms or more of folic acid must comply with these requirements; and
  • All folic acid tablets containing between 100 and 400 micrograms of folic acid must comply with the proposed dissolution requirement, by 25 November 2003, or by a date to be negotiated with the industry.

Item 6 Evaluation of new substance

Item 6.1 Magnesium phosphate dibasic trihydrate

Recommendation 37.4

CMEC recommends to the TGA that magnesium phosphate dibasic trihydrate is suitable for use as an ingredient in listable therapeutic medicines.

Top of page